Abstract: The present invention concerns a contrast agent compound for CEST imaging wherein said contrast agent comprises a proton pool encapsulating system that contains a pool of water mobile shifted protons.

Abstract: The invention relates to high-relaxivity macrocyclic gadolinium chelate oligomers of formula W-(A)m in which W, A and m are as defined in claim 1, and their use as a blood pool contrast product for magnetic resonance imaging.

Abstract: The present invention concerns a diagnostic compound of formula (SCAFFOLD)n1-(LINKER)n3-(SIGNAL)n2-(M),??(E) wherein SCAFFOLD is chosen in table 2: namely Biphenyl; Arylpiperidine; Arylpiperazine; 1,4 dyhydropyridine; Dihydropyrimidone; 1,4 benzodiazepine-2-one; 1,5 benzodiazepine-2-one; 1,4-benzodiazepine-2,5 diones; pyrrolo2,1-c 1,4 benzodiazepines 5,11 diones; 1,4 benzothiazepine-5-ones; 5,11-dihydro-benzo pyrido 3,2b 1,4 diazepine-6-ones Benzopyrane; Chromone; Benzopyranone; Coumarine, pyranocoumarine Benzopiperazinones; Quinazolinone; Quinazolindione; Quinoxalinone Imidazoquinoxaline; indole; Benzimidazole Benzofurane Benzothiophene; SIGNAL is a signal entity for medical imaging diagnostic, and pharmaceutically acceptable salts thereof.

Abstract: The invention relates to novel compounds that are useful for the diagnosis of many pathologies, in particular cardiovascular, cancer-related and inflammatory pathologies, and to pharmaceutical compositions comprising said compounds. These compounds comprise a component for targeting a pathological region, linked to a detection component which is effective in diagnostic terms.

Abstract: The invention relates to new compounds and compositions for the imaging diagnostic of pathologies, namely for cardiovascular diseases, more precisely atherosclerosis disease. These compounds are contrast agents useful namely in the field of magnetic resonance imaging MRI and nuclear medicine. The compounds comprise a particular peptidic MMP inhibitor coupled with a signal entity.

Abstract: The present invention relates to the use, in magnetic resonance imaging employing a field greater than 1.5 Tesla, of a porphyrin compound of the following general formula I in which R0 and R?0 are such that the compound is soluble in a biological medium, and M denotes a paramagnetic metal ion, advantageously Mn3+. The present invention also relates to novel porphyrin compounds.

Abstract: The present invention concerns a diagnostic compound of formula (E) (SCAFFOLD)n1-(LINKER)n3-(SIGNAL)n2-(M), wherein SCAFFOLD is chosen in table 2: namely Biphenyl; arylpiperidine; Arylpiperazine; 1,4 dyhydropyridine Dihydropyrimidone; 1,4 benzodiazepine-2-one; 1,5 benzodiazepine-2-one; 1,4-benzodiazepine-2,5 diones; pyrrolo2,1-c 1,4 benzodiazepines 5,11 diones; 1,4 benzothiazepine-5-ones; 5,11-dihydro-benzo pyrido 3,2b 1,4 diazepine-6-ones; Benzopyrane; Chromone; Benzopyranone; Coumarine, pyranocoumarine; Benzopiperazinones; Quinazolinone; Quinazolindione; Quinoxalinone; Imidazoquinoxaline; indole; Benzimidazole Benzofurane Benzothiophene; SIGNAL is a signal entity for medical imaging diagnostic, and pharmaceutically acceptable salts thereof.

Abstract: The invention relates to a composition comprising acid magnetic particles (p) based on an iron compound, the acid magnetic particles (p) being complexed by one or more gem-bisphosphonate compounds, of formula I

Abstract: Metal chelates of the amides of formula in which R has the formula Use in medical imaging.

Abstract: Chelates of the compounds of formula I in which R is a hydrophilic group containing 3 or 4 successive phenyl rings and m is 1 or 2, with metal ions, for use in diagnostic imaging.